ArticleInternational journal of nanomedicine2026

Poloxamer-Based Th1-Biased NKT Cell Nano-Agonist for Tumor Immunotherapy.

Weiwei Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.